At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 120 target
Drug / intervention
Y-6 sublingual tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: A Phase Ⅱa,Prospective,Multicenter,Randomized, Double-blind,Placebo-controlled Parallel Trial
In Brief
A Phase 2 clinical trial evaluating Y-6 sublingual tablets and Placebo tablets of Y-6 sublingual tablet for Acute Ischemic Stroke and 2 related conditions. Targeting 120 participants across 3 sites.
Detailed Summary
This study aims to evaluate the efficacy of Y-6 sublingual tablets in improving microcirculation dysfunction and reducing thrombo-inflammation in patients who had AIS caused by LVO and received reperfusion therapy. Moreover, we expect to evaluate the safety of using Y-6 sublingual tablet in such study population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke, Reperfusion, Large Vessel Occlusion
CountriesChina
CollaboratorsNeurodawn Pharmaceutical Co., Ltd.
Timeline
Phase 2UnknownOverdue
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionJul 2024
Study CompletionAug 2024
TodayJul 2026
First PostedMay 1, 2023
Enrollment StartJun 5, 2023
Primary CompletionJul 1, 2024
Study CompletionAug 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 3.2 years ago
Interventions
Y-6 sublingual tabletsdrug
Take Y-6 sublingual tablets for 28 days continuously.
Placebo tablets of Y-6 sublingual tabletdrug
Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.